Apex Biotechnology Corp. (TPE:1733)

Market Cap	3.03B +2.9%
Revenue (ttm)	1.91B -2.8%
Net Income	182.14M +13.2%
EPS	1.81 +13.2%
Shares Out	99.95M
PE Ratio	16.73
Forward PE	n/a
Dividend	1.30 (4.35%)
Ex-Dividend Date	Jun 9, 2026

Volume	195,980
Open	29.85
Previous Close	29.90
Day's Range	29.85 - 30.40
52-Week Range	27.00 - 38.70
Beta	0.26
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Apex Biotechnology

Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. It offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing systems. The company also provides pesticide residue check systems; and care management and tele-health services. The company was incorporated in 1997 and is headquartered in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1733

Financial Performance

In 2025, Apex Biotechnology's revenue was 1.94 billion, an increase of 5.00% compared to the previous year's 1.85 billion. Earnings were 162.89 million, an increase of 27.26%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 9, 2026

Data Sources Report a data error